Farmavita.Net - Pharmaceutical Licensing Network - Variant of Tumor Necrosis Factor (TNF)-± : Anti-tumor agent acting on Melanoma & Soft Tissue Sarcoma

Home

Pharma Licensing

Pharma Out-Licensing

Innovative Medicines Offer

Variant of Tumor Necrosis Factor (TNF)-± : Anti-tumor agent acting on Melanoma & Soft Tissue Sarcoma

Pharma Out-Licensing - Innovative Medicines Offer

Variant of Tumor Necrosis Factor

TNF-α has been clinically proven as a tumor killing agent. M3S is a TNF-α Mutein (a variant of TNF-α) proven to have superior anti-tumor activity and safety compared to natural form.

Mechanism of action

TNF-α Mutein (a variant of TNF-α) made from amino acids substitution of TNF-α variant which shown the highest cytotoxicity among variants.

Development status

Approved conditionally.

- Condition : For clinical study only

- Indication : Melanoma, sarcoma and other 3 cancers (liver cancer, breast cancer, ovary cancer)

Patent information

Patent registered in Korea (Reg. No. 123315 / 185330 / 123291), Germany (Reg. No. DE4404124), France (Reg. No. F.P.2701264), USA (USP5773582), Japan (Reg. No. JP2837344) and UK (GB2275683).

Type of business relationship sought

Out-licensing of cell line to produce M3S (Host cell : E.coli)

Full description

Natural TNF-α has known to have tumor killing activity and been studied clinically against cancer patients since late 1980. However, systemic administration of natural TNF-α showed severe adverse reactions. Due to the severe adverse reaction TNF-α treatment has limitation in application.

For production of effective & safe anti-tumor agent derived from TNF-α, a large number of TNF-α variant was produced and a variant with highest cytotoxicity was selected (3S). To eliminate severe toxicity, 3 amino acids of variant were substituted and a part of N-terminal amino acids were deleted (M3S).

M3S has over 10-folds lower toxicity and increased efficacy compared to natural TNF-α. It is for treatment of melanoma and soft tissue sarcoma and other cancers (liver cancer, breast cancer and ovary cancer).

Comments

RSS

Only registered users can write comments!

Read also at Pharmaceutical Licensing Network

< Prev		Next >

Monitoring Downloads Section

You can easily monitor all new articles and reports published at Downloads Section of Farmavita.Net. Click on the RSS button and bookmark this RSS feed. RSS button is located beside title “Farmavita.Net - Pharmaceutical Licensing Network :: File Repository“.